| HOME >> BIOLOGY >> TECHNOLOGY |
- Three New Board Members to Form Audit Committee
NEW YORK and HAIKOU, China, Feb. 5 /Xinhua-PRNewswire-FirstCall/ -- China Pharma Holdings, Inc. ("China Pharma") (OTC Bulletin Board: CPHI) which develops, manufactures, and markets generic and brand bio-pharmaceutical products in China, today announced the appointment of G. Michael Bennett, Yingwen Zhang and Baowen Dong to its Board of Directors, forming the Company's Audit Committee. G. Michael Bennett is Chairman of the Audit Committee. The Company also announced the resignation of Heung Mei Tsui as a member of the Company's Board of Directors, effective February 1, 2008, with no disagreements.
The appointment of Bennett, Zhang and Dong to China Pharma's board brings the total number of directors to five, and the total number of independent non-executive directors to three.
G. Michael Bennett, CPA, is presently a partner of Beijing Nexis Investment Consulting Corporation, which provides management consulting services to Chinese Companies. From 2000 to 2004, he acted as partner of ProCFO Company. Prior to that, he served as CFO and a Board Member in Argonaut Computers. Mr. Bennett worked as professor of accounting, taxation and auditing at several Universities including California State University, Chapman University, University of Hawaii and Chaminade University. Mr. Bennett is a graduate of Michigan State University and Michigan University. He is also a Doctor of Business Administration (DBA) candidate in Corporate Governance at City University of Hong Kong.
Yingwen Zhang is a member of the 9th Chinese People's Political
Consultative Conference (CPPCC). Prior to his current role, Mr. Zhang was
the Economic and Commercial Counselor of the embassy of the People's
Republic of China in Malaysia. Since December 1988, Mr. Zhang has been a
director of Sichuan Foreign Trade and Economic Cooperation Bureau. Prior to
that, he served as the CEO of Sichuan Vinylon Company, a subsid
'/>"/>
| SOURCE China Pharma Holdings, Inc. Copyright©2008 PR Newswire. All rights reserved |